Summary
The binding of [3H]paroxetine and [3H]citalopram to the human brain serotonin (5-HT) uptake site has been characterized and compared. Our results reveal that the binding exclusively involved with the 5-HT uptake site is identical for both [3H]ligands. The selective 5-HT uptake inhibitor citalopram displays the highest affinity for this uptake site, as compared with the affinities obtained for desipramine and norzimeldine, which is in accordance with their respective blockage of 5-HT uptake. Similar Bmax values were obtained for both radioligands in the brain regions studied, indicating their binding to the same presynaptic membrane protein. Together these findings suggest that both [3H]paroxetine and [3H]citalopram are good markers of the 5-HT transporter as both bind selectively and with high affinity to the serotonin uptake sites. However, the higher affinity of [3H]paroxetine confirms that this compound is the best radioligand for the 5-HT uptake site available today.
Similar content being viewed by others
References
Bäckström I, Marcusson J (1987) 5-HT sensitive [3H]imipramine binding of protein nature in the human brain. I. Characteristics. Brain Res 425: 128–136
Bäckström I, Bergström M, Marcusson J (1989) High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486: 261–268
Blakely RD, Berson HE, Fremeau RT, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 66–70
Buus Lassen J (1978) Potent and long lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur J Pharmacol 47: 351–358
Cash R, Raisman R, Ploska A, Agid Y (1985) High and low affinity [3H]imipramine binding sites in control and Parkinsonian brains. Eur J Pharmacol 117: 71–80
Coopen A, Swade C (1988) 5-HT and depression: the present position. In: Briley M, Fillion G (eds) New concepts in depression. Macmillan Press, London, pp 120–136
Cowen PJ (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 159: 7–14
D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH (1987a) Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22: 229–236
D'Amato RJ, Largent BL, Snowman AM, Snyder SH (1987b) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242: 364–371
Fuller R, Wong DT (1990) Serotonin uptake and serotonin uptake inhibition. Ann NY Acad Sci 600: 68–80
Given MB, Longenecker GL (1985) Charcteristics of serotonin uptake and relase by platelets. In: Longenecker GL (ed) The platelets, physiology and pharmacology. Academic Press, New York London, pp 463–479
Graham D (1992) Partial purification and charcterization of the sodium-ice-coupled 5-HT transporter of rat cerebral cortex. J Biochem 286: 801–805
Hardy JA, Wester P, Backstrom I, Gottfries J, Oreland L, Stenstrom A, Winblad B (1987) The regional distribution of dopamine and serotonine uptake and transmitter concentrations in the human brain. Neurochem Int 10: 481–488
Hyttel J (1977) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor, Lu 10–171. Psychopharmacology 51: 225–233
Hyttel J (1982) Citalopram-Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: 277–295
Hyttel J (1982) Citalopram: basic and clinical studies. Prog Neuropsychopharmacol Biol Psychiatry 6: 275–336
Hoffman BJ, Mezey E, Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science 254: 579–580
Hrdina PD, Foy B, Hepiner A, Summers RJ (1990) Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine, localization and relationship to serotonin transporter. J Pharmacol Exp Ther 252: 410–418
Humphreys CJ, Levin J, Rudnick G (1988) Antidepressant binding to the porcine and human platelet serotonin transporters. Mol Pharmacol 33: 667
Johnson AM (1991) The comparative pharmacological properties of selective serotonin uptake inhibitors in animals. In: Feighner JP, Boyer WP (eds) Perspectives in psychiatry: selective serotonin reuptake inhibitors. Wiley, Chichester, pp 37–70
Langer SZ, Javoy Agid F, Raisman R, Briley M, Agid Y (1981) Distribution of specific high affinity binding sites for [3H]imipramine in human brain. J Neurochem 37: 267–271
Langer SZ, Raisman R (1983) Binding of [3H]imipramine and [3H]desipramine as biochemical tools for studies in depression. Neuropharmacology 22: 407–413
Launay JM, Geoffroy C, Mutel V, Buckle M, Cesura A, Alouf JE, Da Prada M (1992) One-step purification of the serotonin transporter located at the human platelet plasma membrane. J Biol Chem 267: 11344–11351
Leake A, Fairbairn AF, McKeith IG, Ferrier N (1992) Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 39: 155–165
Leonard BE (1986) Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review. Hum Psychopharmacol 1: 3–21
Lesch KP, Lerer B (1991) The 5-HT receptor-G-protein-effector system complex in depression. I. Effect of glucocorticoids. J Neural Transm [Gen Sect] 84: 3–18
Marcusson J, Fowler CJ, Hall H, Ross SB, Winblad B (1985) Specific binding of [3H]imipramine to protease sensitive and protease resistant sites. J Neurochem 44: 705–711
Marcusson J, Bäckström I, Ross SB (1986) Single-site model of the serotonin uptake and imipramine binding site. Mol Pharmacol 30: 121–128
Marcusson J, Ross SB (1990) Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology 102: 145–155
Markwell MA, Haas SM, Bieber LL, Tolbert NE (1987) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 203–225
Milne RJ, Goa KL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 450–477
Munson PJ, Rodbard D (1980) LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220–239
Plenge P, Mellerup ET, Laursen H (1990a) Regional distribution of the serotonin transport complex in human brain, identified with [3H]paroxetine, [3H]citalopram and [3H]imipramine. Prog Neuropsychopharmacol Biol Psychiatry 14: 81–72
Plenge P, Mellerup ET, Nielsen M (1990b) Inhibitory and regulatory binding sites on the rat brain serotonin transporter: molecular weight of the [3H]paroxetine and [3H]citalopram binding proteins. Eur J Pharmacol-Mol Pharmacol Sect 189: 129–134
Plenge P, Mellerup ET, Laursen H (1991a) Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol-Mol Pharmacol Sect 206: 243–250
Plenge P, Mellerup ET (1991b) [3H]citalopram binding to brain and platelet membranes of human and rat. J Neurochem 56: 248–252
Racagni G, Brunello N, Tinelli D, Perez J (1992) A new biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry 25: 51–55
Raisman R, Briley M, Langer SZ (1979) Specific tricyclic antidepressant binding sites in rat brain. Nature 281: 148–150
Ross SB (1982) The characteristics of serotonin uptake systems. In: Osborne NN (ed) Biology of serotonergic transmission. Wiley, Chichester, pp 159–195
Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672
Wachtel H (1989) Dysbalance of neural second messenger function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors. J Neural Transm 75: 21–29
Wagner A, Fork P (1987) Molecular approach to the mechanism of action of antidepressant drugs. In: Dahl SG, Gram LF, Paul SM, Poner WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 20–26
Wood M, Broadhurst A, Wyllie M (1986) Examination of the relationship between the uptake system for 5-HT and high affinity [3H]imipramine binding site. Neuropharmacology 25: 516–525
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arranz, B., Marcusson, J. [3H]Paroxetine and [3H]citalopram as markers of the human brain 5-HT uptake site: a comparison study. J. Neural Transmission 97, 27–40 (1994). https://doi.org/10.1007/BF01277960
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01277960